## Financial events: agenda 2011

<table>
<thead>
<tr>
<th>Event</th>
<th>Date * **</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4 Full Year Sales 2010</td>
<td>8 February 2011</td>
</tr>
<tr>
<td>Annual Accounts 2010</td>
<td>24 March 2011</td>
</tr>
<tr>
<td>Q1 Sales 2011</td>
<td>11 May 2011</td>
</tr>
<tr>
<td>Q2 Sales 2011</td>
<td>26 July 2011</td>
</tr>
<tr>
<td>Half Year Results 2011</td>
<td>31 August 2011</td>
</tr>
<tr>
<td>Q3 Sales 2011</td>
<td>9 November 2011</td>
</tr>
</tbody>
</table>

*Subject to modification

**Press releases are distributed after the financial markets closure

### About Stentys

Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, Stentys received the CE mark for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapproach problems associated with conventional stents. Stentys has commenced its marketing activities in several European countries.

*More information on www.stentys.com*

### Contacts:

**Stentys**
Stanislas Piot
CFO
Tel.: +33 (0)1 44 53 99 42
stan.p@stentys.com

**NewCap.**
Investor relations & Financial Communications
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
stentys@newcap.fr

STENTYS is listed on NYSE Euronext Paris
ISIN: FR0010949404 – STNT